FORM 10-Q

                                  United States
                       Securities and Exchange Commission
                             Washington, D. C. 20549

     (Mark One)
         X      Quarterly Report Pursuant to Section 13 or 15(d)
         -           of the Securities Exchange Act of 1934


                       For Quarter Ended: August 31, 2002
                                       OR
         _      Transition Report Pursuant to Section 13 or 15(d)
                     of the Securities Exchange Act of 1934

                         Commission File Number: 0-14820

                                  IMMUCOR, INC.
             (Exact name of registrant as specified in its charter)


             Georgia                                22-2408354
    (State or other jurisdiction of              (I.R.S. Employer
    incorporation or organization)              Identification No.)

          3130 Gateway Drive P.O. Box 5625 Norcross, Georgia 30091-5625
          (Address of principal executive offices)           (Zip Code)


                  Registrant's telephone number: (770) 441-2051

     Indicate  by check mark  whether the  registrant  (1) has filed all reports
required to be filed by Section 13 or 15(d) of the  Securities  Exchange  Act of
1934  during  the  preceding  12 months  (or for such  shorter  period  that the
registrant was required to file such reports),  and (2) has been subject to such
filing requirements for the past 90 days.

                                    Yes X No

     Indicate the number of shares  outstanding of each of the issuer's  classes
of common stock, as of the latest practicable date.

        As of October 4, 2002: Common Stock, $0.10 Par Value - 12,385,264


<PAGE>



<TABLE>
<CAPTION>

                                  IMMUCOR, INC.
                           CONSOLIDATED BALANCE SHEETS
---------------------------------------------------------------------------------------------------------------------------------

                                                                                         August 31, 2002        May 31, 2002
                                                                                      -------------------------------------------
ASSETS                                                                                    (Unaudited)             (Audited)

CURRENT ASSETS:
<S>                                                                                            <C>                   <C>
   Cash and cash equivalents                                                                   $ 5,518,574           $ 4,012,560
   Accounts receivable, trade (less allowance for doubtful accounts of $1,617,655 at
     August 31, 2002 and $1,483,688 at May 31, 2002)                                            26,326,044            27,182,566
   Inventories                                                                                  16,184,778            15,557,034
   Income taxes receivable                                                                         291,513               592,097
   Deferred income taxes                                                                           987,491               987,491
   Prepaid expenses and other                                                                    1,414,575             1,834,521
                                                                                      ---------------------  --------------------

     Total current assets                                                                       50,722,975            50,166,269

LONG-TERM INVESTMENT - At cost                                                                   1,000,000             1,000,000

PROPERTY, PLANT AND EQUIPMENT - Net                                                             17,085,898            17,027,024

DEFERRED INCOME TAXES                                                                              889,906               889,906

OTHER ASSETS - Net                                                                               2,860,056             2,977,130

DEFERRED LICENSING COSTS - Net                                                                   1,301,231             1,370,620

EXCESS OF COST OVER NET TANGIBLE ASSETS ACQUIRED - Net                                          27,983,663            27,936,514
                                                                                      ---------------------  --------------------

                                                                                             $ 101,843,729         $ 101,367,463
                                                                                      =====================  ====================
</TABLE>
















See notes to consolidated financial statements.


<PAGE>

<TABLE>
<CAPTION>

                                  IMMUCOR, INC.
                     CONSOLIDATED BALANCE SHEETS (continued)
----------------------------------------------------------------------------------------------------------------------------------


                                                                                         August 31, 2002        May 31, 2002
                                                                                      --------------------------------------------
LIABILITIES AND SHAREHOLDERS' EQUITY                                                       (Unaudited)             (Audited)

CURRENT LIABILITIES:
<S>                                                                                       <C>                     <C>
   Current portion of borrowings under bank line of credit agreements                     $    1,612,702          $    1,995,630
   Current portion of long-term debt                                                           3,028,395               3,662,304
   Current portion of capital lease obligations                                                  879,257                 975,506
   Accounts payable                                                                            7,550,750               8,136,198
   Income taxes payable                                                                        1,114,991               3,165,247
   Accrued salaries and wages                                                                  1,391,075               1,821,452
   Deferred income taxes                                                                         338,259                 371,404
   Other accrued liabilities                                                                   2,399,959               2,968,701
                                                                                      ----------------------  --------------------

     Total current liabilities                                                                18,315,388              23,096,442


BORROWINGS UNDER BANK LINE OF CREDIT AGREEMENTS - Net of current portion                       2,831,904               3,033,683

LONG-TERM DEBT - Net of current portion                                                       22,745,323              27,294,082

CAPITAL LEASE OBLIGATIONS - Net of current portion                                             1,098,227               1,252,948

DEFERRED INCOME TAXES                                                                          2,076,930               2,035,387

OTHER LIABILITIES                                                                                848,488                 702,047

SHAREHOLDERS' EQUITY:
   Common stock - authorized 45,000,000 shares, $0.10 par value; 12,385,916 and
     11,555,645 issued and outstanding at August 31, 2002 and May 31, 2002,
     respectively                                                                              1,238,591               1,155,563
   Additional paid-in capital                                                                 25,678,596              19,520,658
   Retained earnings                                                                          31,638,152              28,671,351
   Accumulated other comprehensive loss                                                       (4,627,870)             (5,394,698)
                                                                                      ----------------------  --------------------

     Total shareholders' equity                                                               53,927,469              43,952,874
                                                                                      ----------------------  --------------------

                                                                                           $ 101,843,729           $ 101,367,463
                                                                                      ======================  ====================

</TABLE>










See notes to consolidated financial statements.



<PAGE>


<TABLE>
<CAPTION>

                                  IMMUCOR, INC.
                      CONSOLIDATED STATEMENTS OF OPERATIONS
                                   (Unaudited)
--------------------------------------------------------------------------------------------
                                                          August 31,       August 31,
                                                             2002             2001
                                                      ------------------------------------

<S>                                                     <C>              <C>
NET SALES                                               $   23,215,431   $   18,639,962

COST OF SALES                                                9,866,764        9,377,509
                                                        --------------    -------------
GROSS MARGIN                                                13,348,667        9,262,453
                                                        --------------    -------------
OPERATING EXPENSES:
     Research and development                                  365,611          487,012
     Selling and marketing                                   3,336,900        2,829,609
     Distribution                                            1,732,807        1,633,708
     General and administrative                              2,214,220        1,948,919
     Amortization expense                                       72,566          407,811
                                                         --------------    -------------
        Total operating expenses                             7,722,104        7,307,059
                                                         --------------    -------------
INCOME FROM OPERATIONS                                       5,626,563        1,955,394
                                                         --------------    -------------
OTHER INCOME (EXPENSE):
     Interest income                                            45,272            1,068
     Interest expense                                         (814,622)      (1,152,418)
     Other - net                                              (199,182)         672,580
                                                         --------------    -------------
        Total other                                           (968,532)        (478,770)
                                                         --------------    -------------
INCOME BEFORE INCOME TAXES                                   4,658,031        1,476,624
INCOME TAX EXPENSE                                           1,663,553          223,948
                                                         --------------    -------------
NET INCOME                                              $    2,994,478   $    1,252,676
                                                        ===============  ===============
Earnings per share:
     Basic                                                  $ 0.25           $ 0.11
                                                        ===============  ===============
     Diluted                                                $ 0.23           $ 0.11
                                                        ===============  ===============

Weighted average shares outstanding:
     Basic                                                12,181,838       10,916,425
                                                        ================ ================
     Diluted                                              13,190,763       10,944,348
                                                        ================ ================
</TABLE>






See notes to consolidated financial statements.


<PAGE>

<TABLE>
<CAPTION>

                                  IMMUCOR, INC.
                      CONSOLIDATED STATEMENTS OF CASH FLOWS
                                   (Unaudited)
-----------------------------------------------------------------------------------------------------------------------------
                                                                                                 Three Months Ended
                                                                                            August 31,        August 31,
                                                                                            ----------        ----------
                                                                                               2002              2001
                                                                                         ------------------------------------
OPERATING ACTIVITIES:
<S>                                                                                          <C>                <C>
   Net income                                                                                $2,994,478         $1,252,676
   Adjustments to reconcile net income to net cash provided by operating activities:
     Depreciation and amortization of property and equipment                                  1,076,740          1,053,020
     Amortization of other assets and excess of cost over net tangible assets acquired           72,566            407,811
     Amortization of debt issue costs                                                           112,454             20,801
     Provision for doubtful accounts                                                            101,691             90,000
     Disposal of assets in settlement                                                                 -            806,108
     Deferred tax provision                                                                       8,398             54,867
     Changes in operating assets and liabilities:
       Accounts receivable, trade                                                               754,831           (620,286)
       Income taxes                                                                             (70,555)           (79,640)
       Inventories                                                                             (710,974)           (22,018)
       Other current assets                                                                    (100,725)          (923,979)
       Other long-term assets                                                                  (128,935)          (157,032)
       Accounts payable                                                                        (385,448)         1,115,761
       Other current liabilities                                                               (999,119)           246,079
       Other long-term liabilities                                                              146,442             20,131
                                                                                         -----------------  -----------------
         Total adjustments                                                                     (122,634)         2,011,623
                                                                                         -----------------  -----------------

Cash provided by operating activities                                                         2,871,844          3,264,299

INVESTING ACTIVITIES:
   Purchases of / deposits on property and equipment                                           (892,627)        (1,272,123)
                                                                                         -----------------  -----------------

Cash used in investing activities                                                              (892,627)        (1,272,123)

FINANCING ACTIVITIES:
   Borrowings under line of credit agreements net of repayments                              (1,109,732)          (566,487)
   Repayment of long-term debt and capital lease obligations                                 (5,137,550)        (1,141,782)
   Repayment of notes payable                                                                         -           (133,409)
   Payment of debt issue costs                                                                 (200,000)                 -
   Exercise of stock options and warrants (830,272 shares)                                    5,188,666                  -
                                                                                         -----------------  ----------------

Cash used in financing activities                                                            (1,258,616)        (1,841,678)

EFFECT OF EXCHANGE RATE CHANGES ON CASH                                                         785,413            865,871
                                                                                         -----------------  ----------------

INCREASE  IN CASH AND CASH EQUIVALENTS                                                        1,506,014          1,016,369

CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD                                              4,012,560          3,124,517
                                                                                         -----------------  ----------------

CASH AND CASH EQUIVALENTS AT END OF PERIOD                                                   $5,518,574         $4,140,886
                                                                                         =================  ================

</TABLE>

See notes to consolidated financial statements.


<PAGE>


                                  IMMUCOR, INC.
                   Notes to Consolidated Financial Statements
                                   (Unaudited)

1.   BASIS OF PRESENTATION

The accompanying  unaudited consolidated financial statements have been prepared
in accordance with accounting principles generally accepted in the United States
for interim financial  information and the instructions to Form 10-Q and Article
10 of Regulation  S-X.  Accordingly,  they do not include all of the information
and footnotes required by accounting principles generally accepted in the United
States for complete financial  statements.  However,  there has been no material
change in the information disclosed in the Company's annual financial statements
dated May 31, 2002,  except as disclosed  herein.  In the opinion of management,
all adjustments  (consisting of normal recurring accruals)  considered necessary
for  a  fair  presentation  have  been  included.   Operating  results  for  the
three-month  period ended August 31, 2002 are not necessarily  indicative of the
results  that may be  expected  for the year  ending May 31,  2003.  For further
information,  refer  to the  consolidated  financial  statements  and  footnotes
thereto  included in the Company's Annual Report on Form 10-K for the year ended
May 31, 2002.

Certain  prior year balances  have been  reclassified  to conform to the current
year presentation.


2.   INVENTORIES

Inventories are stated at the lower of first-in, first-out cost or market:

<TABLE>
<CAPTION>
                                                      As of                          As of
                                                 August 31, 2002                 May 31, 2002
                                              ----------------------         ----------------------
<S>                                                     <C>                            <C>
Raw materials and supplies                              $ 5,835,914                    $ 5,725,149
Work in process                                           1,679,268                      1,532,821
Finished goods                                            8,669,596                      8,299,064
                                              ----------------------         ----------------------
                                                        $16,184,778                    $15,557,034
                                              ======================         ======================
</TABLE>


3.   EARNINGS PER SHARE

The following table sets forth the computation of basic and diluted earnings per
share in accordance with Statement of Financial  Accounting  Standards  ("SFAS")
No. 128, Earnings per Share. The Company implemented a three-for-two stock split
on September 13, 2002 to  shareholders  of record as of the close of business on
August 26, 2002. The split was effected in the form of a 50% stock dividend. All
share and per share  amounts  disclosed in this  document  have been restated to
reflect  this stock  split  discussed  in Note 8 to the  Consolidated  Financial
Statements.

<TABLE>
<CAPTION>
                                                             Three Months Ended
                                                         August 31,       August 31,
                                                            2002             2001
                                                       ---------------- ---------------
<S>                                                         <C>             <C>
Numerator for basic and diluted earnings per share:
Income available to common shareholders                     $2,994,478      $1,252,676
                                                       ================ ===============
Denominator:
  For basic earnings per share - weighted
         average basis                                      12,181,838      10,916,425
  Effect of dilutive stock options and warrants              1,008,925          27,923
                                                       ---------------- ---------------
  Denominator for diluted earnings per
     share-adjusted weighted-average shares                 13,190,763      10,944,348
                                                       ================ ===============

Basic earnings per share                                         $0.25           $0.11
                                                       ================ ===============

Diluted earnings per share                                       $0.23           $0.11
                                                       ================ ===============
</TABLE>
<PAGE>

4.   DOMESTIC AND FOREIGN OPERATIONS

Information   concerning  the  Company's  domestic  and  foreign  operations  is
summarized below (in 000s):
<TABLE>
<CAPTION>

                               ---------------------------------------------------------------------------------------------------
                                                               Three Months Ended August 31, 2002
                               ---------------------------------------------------------------------------------------------------
                                 U.S.         Germany       Italy         Canada        Other       Eliminations     Consolidated
Net reagent sales:
<S>                             <C>            <C>          <C>            <C>          <C>         <C>                  <C>
   Unaffiliated customers       $15,673        $2,222       $1,467         $1,457       $1,194      $        -           $22,013
   Affiliates                     1,756           105            4             37           80          (1,982)                -
                               ----------    ----------    ---------     ----------    ---------    -------------    -------------
      Total                      17,429         2,327        1,471          1,494        1,274          (1,982)           22,013
Net instrument sales:
   Unaffiliated customers           755           199            -              -          248               -             1,202
   Affiliates                        18           365            -              -            -            (383)                -
                               ----------    ----------    ---------     ----------    ---------    -------------    -------------

      Total                         773           564            -              -          248            (383)            1,202

Income (loss) from operations     5,179            60          (38)           321          188             (83)            5,627
Net income (loss)                 2,734            (1)         (15)           161          164             (49)            2,994

                               ---------------------------------------------------------------------------------------------------
                                                               Three Months Ended August 31, 2001
                               ---------------------------------------------------------------------------------------------------
                                 U.S.         Germany       Italy         Canada        Other       Eliminations     Consolidated
Net reagent sales:
   Unaffiliated customers       $11,817        $2,173       $1,396         $1,297       $1,121      $        -           $17,804
   Affiliates                     1,826            66            -             32          104          (2,028)                -
                               ----------    ----------    ---------     ----------    ---------    -------------    -------------
      Total                      13,643         2,239        1,396          1,329        1,225          (2,028)           17,804
Net instrument sales:
   Unaffiliated customers           651            37           28              -          120               -               836
   Affiliates                        33           289            -              -            -            (322)                -
                               ----------    ----------    ---------     ----------    ---------    -------------    -------------

      Total                         684           326           28              -          120            (322)              836

Income from operations            1,134           202          121            346          175             (23)            1,955
Net income (loss)                 1,378           123         (134)           100          (75)           (139)            1,253
</TABLE>

The Company's U.S. operations made net export sales to unaffiliated customers of
approximately  $1,235,000  and  $1,306,000 for the three months ended August 31,
2002 and 2001,  respectively.  The Company's  German  operations made net export
sales to unaffiliated  customers of approximately  $640,000 and $897,000 for the
three  months  ended  August  31,  2002 and 2001,  respectively.  The  Company's
Canadian  operations  made  net  export  sales  to  unaffiliated   customers  of
approximately  $620,000  and $570,000 for the three months ended August 31, 2002
and 2001, respectively. Product sales to affiliates are valued at market prices.


5.   COMPREHENSIVE INCOME

The components of comprehensive  income for the three-month periods ended August
31, 2002 and 2001 are as follows:
<TABLE>
<CAPTION>
                                                       Three Months Ended
                                                August 31,           August 31,
                                                   2002                 2001
                                              ----------------     ----------------

<S>                                            <C>                  <C>
Net income                                     $  2,994,478         $  1,252,676
Net foreign currency translation                    761,691              951,502
Cumulative effect of the adoption of FAS
   133 on June 1, 2001, net of taxes                      -             (102,721)
Hedge loss reclassified into earnings                 5,137                    -
                                              ----------------     ----------------
Comprehensive income                           $  3,761,306         $  2,101,457
                                              ================     ================
</TABLE>

Accumulated  comprehensive  loss as of  August  31,  2002  and May 31,  2002 was
($4,627,870) and ($5,394,698),  respectively.  The balance, consisting primarily
of net losses on foreign  currency  translation  adjustments and fluctuations in
the fair value of the Company's  interest rate swaps,  has been disclosed in the
shareholders' equity section of the consolidated balance sheets.
<PAGE>


6.   IMPACT OF RECENTLY ISSUED ACCOUNTING STANDARDS

In June 1998, the Financial  Accounting Standards Board ("FASB") issued SFAS No.
133,  Accounting  for  Derivative  Instruments  and  Hedging  Activities.   This
statement  provides a comprehensive and consistent  standard for the recognition
and  measurement of derivatives and hedging  activities.  In June 2000, the FASB
issued SFAS No. 138,  Accounting for Certain Derivative  Instruments and Certain
Hedging  Activities-an  Amendment  to FASB  Statement  No. 133.  This  statement
amended  certain  provisions of SFAS No. 133.  Accordingly,  the Company adopted
SFAS No. 133, as amended by SFAS No. 138,  effective the first quarter of fiscal
2002.  The  cumulative  effect of the  adoption  of SFAS No. 133 on June 1, 2001
resulted in a  comprehensive  loss (a component of  Shareholders'  Equity on the
balance  sheet) of  approximately  $103,000,  net of  $26,000  in income  taxes,
relating to the interest rate swap agreements.  Since the swap agreement related
to the  Canadian  line of credit  matured in December  2001,  an  adjustment  of
approximately  $15,000  was  made to  comprehensive  loss  and  reclassified  to
earnings as interest expense in fiscal 2002. Due to the  ineffectiveness  of the
swap  related to the U. S. loan,  approximately  $16,000 was  reclassified  from
comprehensive  loss to earnings as interest expense and  approximately  $267,000
was charged directly to interest  expense in fiscal 2002. The remaining  balance
of approximately  $72,000 will be amortized over the remaining term of the loan.
Approximately $5,100 of this ineffectiveness was charged to interest expense for
the period  ended  August 31,  2002,  and  approximately  $116,000  was  charged
directly to interest expense in the first quarter of fiscal 2003.

See Note 9 of the consolidated financial statements for a discussion of SFAS No.
141,  Business  Combinations  and SFAS No. 142,  Goodwill  and Other  Intangible
Assets.

In October 2001, the FASB issued SFAS No. 144,  Accounting for the Impairment or
Disposal of Long-Lived Assets. The Statement supercedes SFAS No. 121, Accounting
for the Impairment of Long-Lived Assets and for Long-Lived Assets to be Disposed
of, however it retains the fundamental  provisions of that statement  related to
the  recognition  and  measurement of the impairment of long-lived  assets to be
"held and used." The  Statement  is  effective  for  year-ends  beginning  after
December  15, 2001.  The Company  adopted  SFAS No. 144  effective  June 1, 2002
without impact on its financial position or results of operations.

7.   INCOME TAXES

Income  tax  expense  for the period  ended  August  31,  2002 of  approximately
$1,664,000 was greater as a percentage of pre-tax income than income tax expense
of approximately $224,000 as a percentage of pre-tax income for the period ended
August 31, 2001  primarily  due to net  operating  loss  carryforwards  utilized
during the prior year.


8.   STOCK SPLIT

On July 24, 2002, the Board of Directors  approved a three-for-two  stock split,
which was effected in the form of a 50% stock dividend. The date of distribution
was September 13, 2002 to the shareholders of record at the close of business on
August 26, 2002.  The number of shares  outstanding  at the close of business on
August 26, 2002 was  8,257,277.  The stock split added an  additional  4,128,639
shares to outstanding  shares. All share and per share amounts disclosed in this
document  have been  restated to reflect this stock  split.  The total number of
shares outstanding at the stock split pay date was 12,385,916.


9.   ADOPTION OF NEW ACCOUNTING STANDARD

In June 2001, the FASB issued SFAS No. 141, Business Combinations,  and SFAS No.
142,  Goodwill and Other Intangible  Assets.  Under the new rules,  goodwill and
indefinite  lived  intangible  assets are no longer  amortized  but are reviewed
annually for impairment,  or more frequently if impairment indicators arise. The
review process will entail assessing the fair value of the net assets underlying
the Company's  acquisition  related goodwill on a business by business basis. If
the fair value is deemed less than the related  carrying value, the Company will
be required to reduce the amount of the goodwill.  These reductions will be made
retroactive to June 1, 2002.  Separable intangible assets that are not deemed to
have an indefinite life will continue to be amortized over their useful lives.

The  Company has applied the new  accounting  rules to goodwill  and  intangible
assets,  all of which were  acquired  prior to July 1, 2001,  during the quarter
ending August 31, 2002. As of August 31, 2002, the financial statements included
acquisition related goodwill of $26.6 million,  net of previous  amortization of
$6.8  million.  Goodwill,  net of  amortization,  totaled  $18.3  million,  $1.7
million,  $0.7  million,  $5.7  million and $0.2  million in the U.S.,  Germany,
Italy, Canada, and other, respectively. The process of implementing SFAS No. 142
has begun  and will be  completed  during  the first  half of fiscal  2003.  The
Company does not expect a substantial  reduction in goodwill as a result of this
process.  In  addition,  the  Company no longer  amortizes  acquisition  related
goodwill.  The table below shows the periods ended August 31, 2002 and 2001 on a
comparative basis given the adoption of the amortization provisions of SFAS 142.


<PAGE>


<TABLE>
<CAPTION>

                                                                 Quarters ended
                                                          August 31,        August 31,
                                                             2002              2001
                                                        ---------------- -----------------

     <S>                                                    <C>              <C>
     Net income as reported                                 $2,994,478       $1,252,676
     Add:  Goodwill amortization, net of taxes                       -          215,864
                                                            -----------      -----------
     Net income as adjusted for SFAS No. 142                $2,994,478       $1,468,540

     Net income per basic share:
          As reported                                            $0.25            $0.11
          As adjusted                                            $0.25            $0.13

     Net income per diluted share:
          As reported                                            $0.23            $0.11
          As adjusted                                            $0.23            $0.13

</TABLE>


Excess  of Cost  Over Net  Tangible  Assets  Acquired  includes  a $1.7  million
customer list.  Accumulated  amortization  of the customer list as of August 31,
2002 and May 31, 2002, was $0.3 million and $0.3 million, respectively.

The  customer  list is being  amortized  over a  useful  life of 20  years.  The
estimated  amortization  expense  relating to the customer  list for each of the
next five fiscal years is as follows:

                    2003                             $  85,000
                    2004                                85,000
                    2005                                85,000
                    2006                                85,000
                    2007                                85,000
                    Thereafter                         970,000
                                          ---------------------
                                                   $ 1,395,000
                                          =====================


9.  LOAN AMENDMENT

On July 18, 2002, the Company amended the loan agreement. The amendment extended
the term of the lines of credit  from  February  28,  2003 to  December 1, 2005.
Borrowings  under the senior credit facility will be priced subject to a pricing
grid that varies based upon the Company's  Funded Debt to EBITDA,  as defined in
the senior  credit  facility.  The interest  rate on the  effective  date of the
amendment was LIBOR plus 200 basis points on the  revolving  lines of credit and
Term Loan A and LIBOR plus 250 basis  points on Term Loan B. At August 31,  2002
there was approximately  $23.9 million  outstanding under the revolvers and Term
Loan A and approximately $6.0 million outstanding under Term Loan B. The Company
made a $4.5 million  payment  against the revolving line of credit in July 2002.
Pricing under the amendment did not change from the original loan agreement


ITEM 2. Management's  Discussion and Analysis of Financial Condition and Results
        of Operations.

Certain statements that Immucor may make from time to time, including statements
contained  in this report,  constitute  "forward-looking  statements"  under the
federal securities laws.  Forward-looking  statements may be identified by words
such as "plans," "expects," "believes," "anticipates,"  "estimates," "projects,"
"will" and other words of similar meaning used in conjunction  with, among other
things,  discussions  of  future  operations,   financial  performance,  product
development and new product launches, market position and expenditures.  Factors
that could cause actual results to differ materially from those expressed in any
forward-looking  statement  made  by,  or on  behalf  of,  Immucor  include  the
following,  some of which are described in greater detail below: the decision of
customers  to  defer  capital  spending,  increased  competition  in the sale of
instruments  and  reagents,  changes  in  interest  rates and  general  economic
conditions.  In addition,  the strengthening of the dollar versus the Euro would
adversely impact reported European results. Investors are cautioned not to place
undue  reliance  on  any  forward-looking  statements.   Immucor  cautions  that
historical   results  should  not  be  relied  upon  as  indications  of  future
performance.  Immucor  assumes  no  obligation  to  update  any  forward-looking
statements.



<PAGE>



Critical Accounting Policies

General

We have identified the policies below as critical to our business operations and
the  understanding  of our results of operations.  The impact and any associated
risks  related  to  these  policies  on our  business  operations  is  discussed
throughout  Management's  Discussion  and  Analysis of Financial  Condition  and
Results of  Operations  where such  policies  affect our  reported  and expected
financial  results.  For a detailed  discussion on the  application of these and
other accounting policies,  see Note 1 and Note 6 to the Consolidated  Financial
Statements of this Quarterly  Report on Form 10-Q.  Note that our preparation of
this Form 10-Q  requires us to make  estimates and  assumptions  that affect the
reported amounts of assets and liabilities,  disclosure of contingent assets and
liabilities at the date of our financial statements, and the reported amounts of
revenue and expenses during the reporting period. There can be no assurance that
actual results will not differ from those estimates.

Revenue Recognition

The Company recognizes revenue in accordance with SEC Staff Accounting  Bulletin
No. 101, Revenue Recognition in Financial  Statements ("SAB 101"), as amended by
SAB 101A and 101B.  SAB 101 requires that four basic criteria must be met before
revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2)
delivery  has  occurred  or  services  rendered;   (3)  the  fee  is  fixed  and
determinable;  and (4) collectibility is reasonably  assured.  Should changes in
conditions  cause management to determine these criteria are not met for certain
future  transactions,  revenue  recognized  for any  reporting  period  could be
adversely  affected.  Revenue  from  the  sale  of  the  Company's  reagents  is
recognized  upon  shipment  since both title and risk of loss  transfers  to the
customer  upon  shipment.  Revenue  from  the  sale  of  the  Company's  medical
instruments   is  recognized   upon  shipment  and   completion  of  contractual
obligations  relating  to  training  and/or  installation  based on terms of the
related agreements. Revenue from rentals of the Company's medical instruments is
recognized over the life of the rental agreement.

Allowance for Doubtful Accounts

Immucor  maintains   allowances  for  doubtful  accounts  for  estimated  losses
resulting  from the inability of its customers to make  required  payments.  The
allowance is approximately 6.1% of the accounts receivable balance.  The Company
continually  monitors  the  collectibility  of its  customer  accounts  and when
indications  arise that  amounts are not likely to be  collected,  the amount is
charged to the allowance for doubtful  accounts.  If the financial  condition of
Immucor's  customers  were to  deteriorate,  resulting in an impairment of their
ability to make payments, additional allowances could be required.

Inventory

Inventories are stated at the lower of first-in,  first-out cost or market. Cost
includes material, labor and manufacturing overhead. The Company uses a standard
cost system that applies labor and  manufacturing  overhead factors to inventory
based on budgeted  production  levels,  staffing  levels and costs of operation.
Actual  costs  and  production  levels  may vary from the  standard  and will be
charged to the  consolidated  statement of  operations as a component of cost of
sales.

Goodwill and Other Long-lived Assets

In assessing the  recoverability of the Company's  goodwill and other long-lived
assets the Company must make assumptions  regarding  estimated future cash flows
and other factors to determine the fair value of the respective assets. If these
estimates or their related  assumptions change in the future, the Company may be
required to record impairment charges for these assets not previously  recorded.
On June 1, 2002 the Company adopted Statement of Financial  Accounting Standards
("SFAS") No. 142, Goodwill and Other Intangible  Assets, and will be required to
analyze its goodwill and intangible  assets for impairment on an annual basis or
more frequently if impairment indicators arise. In October 2001, the FASB issued

<PAGE>

SFAS No. 144,  Accounting for the  Impairment or Disposal of Long-Lived  Assets.
The  Statement  supercedes  SFAS  No.  121,  Accounting  for the  Impairment  of
Long-Lived  Assets  and for  Long-Lived  Assets to be  Disposed  of,  however it
retains the fundamental  provisions of that statement related to the recognition
and  measurement of the  impairment of long-lived  assets to be "held and used."
The Company  adopted SFAS No. 144 effective  June 1, 2002 without  impact on its
financial position or results of operations.

Income Taxes

Our income tax policy  records the  estimated  future tax  effects of  temporary
differences between the tax bases of assets and liabilities and amounts reported
in the accompanying  consolidated  balance sheets, as well as operating loss and
tax credit  carry-forwards.  We follow very  specific  and  detailed  guidelines
regarding the recoverability of any tax assets recorded on the balance sheet and
provide any  necessary  allowances  as required.  The Company  believes that the
value of the Company's net deferred tax assets  assumes that the Company will be
able to generate  sufficient future taxable income in certain tax jurisdictions,
based on estimates and assumptions.  If these estimates and related  assumptions
change in the future, the Company may be required to record additional valuation
allowances  against its deferred tax assets  resulting in additional  income tax
expense in the Company's consolidated statements of operations. In assessing the
realizability of deferred tax assets,  management  considers  whether it is more
likely than not that some  portion or all of the deferred tax assets will not be
realized.   Management   considers  the  scheduled   reversal  of  deferred  tax
liabilities,  projected future taxable income, carry back opportunities, and tax
planning  strategies  in  making  this  assessment.   Management  evaluates  the
realizability  of the deferred  tax assets and assesses the need for  additional
valuation allowances quarterly.


Financial Condition

As of August 31, 2002, the Company's cash and cash  equivalents  balance totaled
$5.5 million, an improvement of $1.5 million over the quarter ended May 31, 2002
and $1.4 million over the quarter ended August 31, 2001. Net working capital for
the period ended August 31, 2002 increased to $32.5  million,  an improvement of
$5.3  million,  from $27.1  million  for the  quarter  ended May 31, 2002 and an
improvement of $11.0 million, from $21.4 million for the period ended August 31,
2001.  The  price  increases  implemented  in  fiscal  2002  have  significantly
strengthened the Company's  financial  position.  As a consequence,  the Company
experienced  a rise in the value of its stock and, as a result,  option  holders
have exercised a large number of options bringing an additional  influx of cash.
The  effect of  exchange  rate  changes  increased  cash at August  31,  2002 by
approximately $0.8 million from May 31, 2002.

Net cash provided by operating  activities  totaled  approximately $2.9 million,
$3.9  million,  and $3.3 million for the  three-month  periods  ended August 31,
2002, May 31, 2002 and August 31, 2001,  respectively.  During the quarter ended
August 31,  2002,  the  Company  improved  net income by $0.2  million  over the
quarter  ended May 31, 2002 and $1.7 million  over the quarter  ended August 31,
2001  that  included  one-time  benefits  of  $0.2  million  and  $0.8  million,
respectively,  for a legal settlement.  Revenues were relatively consistent with
the quarter  ended May 31, 2002 and $4.6 million  higher than the quarter  ended
August 31, 2001,  as a result of reagent price  increases in the United  States.
Gross  margin,  as a  percentage  of sales,  was 57.5%,  58.2% and 49.7% for the
three-month  periods  ended August 31,  2002,  May 31, 2002 and August 31, 2001,
respectively.  The current  quarter was  affected by  unfavorable  manufacturing
variances which are expected to improve over the course of the fiscal year.

During the  quarter  ended  August 31,  2002,  $0.9  million of cash was used in
investing activities for capital expenditures which included  approximately $0.4
million for  expansion of the  Company's  computer  network  capabilities,  $0.2
million to refurbish the German facility and $0.3 million for  manufacturing and
quality  system  improvements  at its Norcross and Houston  facilities.  Planned
capital  expenditures  for fiscal 2003 total  approximately  $4.1  million,  and
include  approximately $0.3 million for U.S. clinical trial Galileo instruments,
approximately $1.3 million for Galileo reagent rental  instruments  installed in
Europe,  $1.3 million for manufacturing  and quality system  improvements at its
domestic manufacturing facilities and $1.2 million for expansion of its computer
network capabilities.
<PAGE>


Net cash used in financing activities totaled $1.3 million.  During the quarter,
the Company paid $6.4 million of  long-term  debt,  debt issue costs and capital
lease obligations.  However,  the Company received $5.2 million in cash from the
exercise of stock options.  These options were granted in prior fiscal years and
provided for exercise prices equal to the market value of the Company's stock on
the date  granted.  The  Company  experienced  a rise in the  value of its stock
during the recently  completed  fiscal year and as a result option  holders have
exercised a large number of options.

Accounts  receivable  decreased by approximately  $0.8 million from May 31, 2002
due to improved  U.S.  collections.  Inventory  increased  $0.7  million for the
period with the purchase of Galileo instruments for product launch, the purchase
of  additional  Rosys   instruments,   the  timing  of  receipt  of  third-party
distributed product and the increase in shipping supplies for the implementation
of  a  new  shipping  package  configuration  designed  to  maintain  acceptable
environmental  temperature  and preserve  product  quality during  shipment.  In
August  2002,  Immucor  placed  an  order,  amounting  to $3.3  million,  for 50
additional ABS2000 instruments to be delivered starting in February 2003. Income
tax refund  receivable  decreased due to the refund of tax  overpayments  in the
German  subsidiary.  Prepaid  and other  assets  decreased  by $0.1  million due
primarily to receipts of amounts due from financial  institutions  upon exercise
of stock options.  Other long-term  assets decreased in the quarter ended August
31, 2002  primarily as a result of  amortization  of debt issue costs.  Deferred
licensing costs declined due to normal  amortization and excess of cost over net
tangible assets  acquired  increased due to the exchange rate effect of the Euro
on the Company's European subsidiaries.

Accounts payable decreased by $0.4 million due to increased funds available from
the exercise of stock options. The current income tax liability decreased due to
estimated  tax  payments  made  during the  quarter  and the tax benefit of $1.7
million  related  to the  stock  option  exercises.  Other  current  liabilities
decreased by $1.0 million as the May 31, 2002  year-end  accrual for  executive,
management  and  supervisory  bonuses and other  accruals  for legal,  audit and
royalties fees were paid during the current quarter. Other long-term liabilities
increased by $0.1 million  primarily  due to the change in value of the interest
rate swap agreement.

Common stock and additional  paid-in  capital  increased by an aggregate of $6.6
million primarily due to the exercise of stock options, described above, and the
related  tax  benefit.  Also,  common  stock  increased  and  retained  earnings
decreased by $0.4 million due to the effect of the three-for-two  stock split on
September 13, 2002. Retained earnings and (comprehensive  loss) improved by $3.3
million  due to the  earnings  for the year  and  favorable  changes  in the net
foreign exchange  translation.  The financial statements of foreign subsidiaries
have been translated into U.S. dollars in accordance with FASB Statement No. 52,
Foreign  Currency  Translation.  All balance sheet accounts have been translated
using the exchange rates in effect at the balance sheet dates.  Income statement
amounts have been translated  using the average  exchange rates for each period.
The gains and losses  resulting  from the changes in exchange rates from year to
year have been  reported  separately  as a  component  of  comprehensive  income
(loss).  The effect of foreign  currency  transaction  gains and losses has been
recorded in the accompanying statements of operations.

In July,  2002,  the Company and its primary lender amended their loan agreement
to extend the term of the existing  revolving  lines of credit from February 28,
2003 to December  1, 2005.  Borrowings  under the senior  credit  facility  were
re-priced  according  to a price that varies based upon the  Company's  ratio of
Funded Debt to EBITDA,  as defined in the senior credit  facility.  The interest
rate on the effective date of the amendment was LIBOR plus a spread of 200 basis
points on the revolving  lines of credit and Term Loan A and LIBOR plus a spread
of 250 basis points on the Term Loan B.

Management  is focused on reducing the leverage on the  Company's  balance sheet
and does not  anticipate  that there will be a need for  additional  borrowings.
Management expects that cash and cash equivalents and internally generated funds
will be sufficient to support operations,  scheduled debt repayments and planned
capital  expenditures  for the next 12 months,  as well as fund future long-term
debt payments.



<PAGE>



Results of Operations

For the quarter ended August 31, 2002 revenues  totaled  $23.2  million,  a $4.6
million,  or 24.5% increase over the quarter ended August 31, 2001. The increase
in revenues occurred predominantly as a result of reagent price increases in the
United  States.  Income before income taxes reached $4.7 million for the quarter
compared to income  before tax of $1.5 million for the prior year  quarter.  Net
income  increased to $3.0 million  versus net income of $1.3 million in the same
period last year. Diluted earnings per share were $0.23 on 13.2 million weighted
average shares outstanding  compared with $0.11 on 10.9 million weighted average
shares outstanding,  adjusted for the three-for-two stock split on September 13,
2002, for the same period last year. The rise in the Company's  stock price over
the past year has increased the dilutive effect of stock options and warrants by
approximately 1.0 million shares that are used to arrive at diluted earnings per
share. Earnings before interest,  taxes,  depreciation and amortization (EBITDA)
were $6.6 million and compare favorably with last year's EBITDA,  (excluding the
$0.8 million Becton Dickson settlement), of $3.2 million.

Net sales

Reagent  revenues grew to $22.0  million  compared to $17.8 million in the first
quarter of fiscal 2001, a 23.6% increase. The Company believes growth in reagent
revenue occurred as a result of price increases in North America,  new customers
and volume increases in proprietary  Capture(R)  products.  Sales of instruments
during the quarter were better than expected at $1.2 million as compared to $0.8
million  in  the  previous  year.  Instrument  sales  grew  as a  result  of new
placements  and  concentrated  efforts  to reduce  the  backlog  of  instruments
installed  but not recorded as revenue due to post  installation  criteria.  The
instrument  backlog currently stands at $0.7 million.  The effect on revenues of
the change in the Euro exchange rate was an increase of $645,000 for the quarter
ended August 31, 2002.

Cost of Sales

Cost of sales, as a percentage of sales, totaled 42.5% versus 50.3% for the same
period in the prior year. Cost of sales increased approximately $0.5 million, as
compared  to the prior  year.  The  effect on cost of sales of the change in the
Euro exchange rate accounted for approximately  $0.3 million of the increase and
the remainder was as a result of unfavorable  manufacturing  variances which are
expected to improve over the course of the fiscal year.

Operating expenses

When compared to the prior year,  research and development costs for the quarter
ended  August 31,  2002  declined  24.9% from the prior  year  period  primarily
related to a reduction of instrument  development  initiatives  with the initial
launch of the Galileo in the European  market.  The instrument is being marketed
exclusively  by Immucor to  hospital  transfusion  laboratories  and blood donor
centers  for  patient  and  donor  blood  typing  and  antibody   screening  and
identification.

Selling and  marketing  expenses  increased  $0.5 million for the quarter  ended
August 31, 2002 as compared to the prior year period. The domestic reagent price
increases  resulted in an equivalent rise in  commissions.  Travel and marketing
expenses increased with sales effort in Europe to market the Galileo.

Distribution  expenses for the quarter  ended August 31, 2002  increased by $0.1
million  compared to the prior year.  There were  additional  shipping  expenses
related  to  new  customers  and  volume  increases  in  proprietary  Capture(R)
products, as well as, the implementation of a new shipping package configuration
designed to maintain acceptable  environmental  temperature and preserve product
quality during shipment.

General and  administrative  expenses for the quarter ended August 31, 2002 rose
approximately  $0.3  million,  but declined as a percentage of sales to 9.5% for
the quarter  ended  August 31, 2002 from 10.5% for the quarter  ended August 31,
2001. The increase was largely due to increased  professional  fees for computer
software  improvements  as the Company  began its second year on its  enterprise
software system.
<PAGE>

Amortization expense declined $0.3 million as compared with the prior period due
to the adoption of SFAS  No.142,  Goodwill and Other  Intangible  Assets,  which
requires goodwill and indefinite lived intangible assets to be reviewed annually
for  impairment,  or more  frequently if impairment  factors  arise,  instead of
amortized. The Company does not currently note any indications of impairment and
expects amortization will be approximately $1.2 million less in fiscal 2003 than
in fiscal 2002.

Interest expense

When compared to the prior year,  interest expense decreased $0.3 million in the
quarter  ended  August 31,  2002.  The  decrease  is the  result of the  reduced
borrowings  on long-term  debt and a more  favorable  interest  rate that became
effective in May 2002 under the original loan  agreement and continued  with the
July 2002 amendment to the loan agreement.  The amortization of debt issue costs
that is charged to interest  expense was lower in the current quarter due to the
reset of the long-term debt maturity dates.

Other income (expense)

Other  income for the first  quarter of fiscal 2002 was  positively  impacted by
$0.8 million  from the  settlement  of the Becton,  Dickinson  arbitration.  The
settlement  called for  Becton to pay  Immucor,  Inc.  a total of $1.8  million,
payable in two  installments,  with a $1.2 million payment received in the first
quarter of 2002. The current quarter other expense  primarily  reflected foreign
currency translation losses that exceeded foreign currency translation gains.

Income taxes

Income tax expense  increased for the quarter ended August 31, 2002, as compared
to the prior period,  due to higher income in the current period and utilization
of net operating  loss  carry-forwards  in the prior  period.  During the fourth
quarter of fiscal 2001, the Company  elected to record a valuation  allowance in
an amount equal to the net deferred tax assets of the Company, amounting to $1.2
million.  Effectively,  this non-cash  allowance  reflected the  elimination  of
domestic deferred taxes as a balance sheet asset and was used to reduce domestic
taxes in fiscal 2002. The net operating loss carry-forwards  generated in fiscal
2001 also  reduced the fiscal 2002 United  States tax  provision  and were fully
utilized by the quarter ended February 28, 2002.

Competition

Competition is based on quality of product,  price, sales force talent,  ability
to  furnish  a  range  of  existing  and new  products,  customer  services  and
continuity of product  supply.  During the past several years,  the industry has
experienced aggressive price competition,  particularly among manufacturers that
target large  hospitals  and  institutions  as key  customers.  In spite of this
competitive  environment,  the Company has  maintained  its worldwide  sales and
increased its domestic  reagent market share.  Management  believes that this is
due to the  Company's  emphasis  on product  quality,  the  introduction  of new
products,  specialty products, customer service and training. With the Company's
fiscal 1999  purchases of Gamma and the assets of the BCA blood bank division of
Biopool   International,   Inc.,  the  Company   believes  that  Ortho  Clinical
Diagnostics,  a Johnson  &  Johnson  company,  is now its sole  competitor  with
licenses to manufacture a complete line of blood banking  reagents in the United
States.  The Company believes that it became the North American market leader in
terms of sales during fiscal 1999.

Olympus  America  Inc. has  developed an automated  analyzer for the blood donor
market.  The  instrument  performs  only  ABO/Rh  testing  and does not  perform
antibody screening. The Olympus instrument users currently dilute commercial ABO
and  Rh  reagents  for  the  machine's  use.  Gamma  began  developing   diluted
ready-for-use  reagents  for  Olympus  several  years  ago.  Gamma has  received
clearance from the FDA for six of the reagents and is awaiting clearance for the
seventh.  Management does not believe the Olympus instrument will have an effect
on its instrument strategy in North America.
<PAGE>

Biotest AG, a German  Pharmaceutical and Diagnostic  company,  presently has FDA
licenses  for six reagent  products.  Management  does not believe  Biotest will
provide a material competitive threat in the U.S. in the near future since their
product line is  incomplete  and there is no evidence  that Biotest will be in a
position,  in the near term,  to market a complete  commercially-viable  product
line.

European competitors for blood bank products include Biotest and Diamed, a Swiss
company.  Both of these companies have been established  longer than the Company
and may have greater financial and other resources than the Company.  Diamed has
a larger global  market share than the Company.  However,  the Company  believes
that it is well  positioned  to compete  favorably in the  business  principally
because  of the  completeness  of its  product  line,  quality  and price of its
products,  the sale of innovative  products such as blood bank  automation,  the
Company's Capture(R) products,  continuing research efforts in the area of blood
bank  automation,  the experience  and expertise of its sales  personnel and the
expertise of its technical and customer support staff.


ITEM 3. Quantitative and Qualitative Disclosures On Market Risk

There have been no material changes regarding the Company's market risk position
from the  information  provided in its Annual Report on Form 10-K for the fiscal
year ended May 31, 2002. The  quantitative  and  qualitative  disclosures  about
market risk are discussed in Item  7A-Quantitative  and Qualitative  Disclosures
About Market Risk, contained in the Company's Annual Report on Form 10-K.



ITEM 4. Controls and Procedures.


Within the 90 days prior to the date of this report,  the Company carried out an
evaluation,  under the supervision and with the  participation  of the Company's
management,  including the Company's Chief Executive Officer and Chief Financial
Officer,  of the  effectiveness  of the design and  operation  of the  Company's
disclosure controls and procedures  pursuant to Exchange Act Rule 13a-14.  Based
upon that evaluation,  the Chief Executive  Officer and Chief Financial  Officer
concluded that the Company's  disclosure  controls and procedures are effective.
There were no significant changes in the Company's internal controls or in other
factors that could significantly affect these controls subsequent to the date of
their evaluation.


                                     PART II

                                OTHER INFORMATION

ITEM 6.  Exhibits  and  Reports  on Form  8-K.

(a) The  Company  has  filed the following exhibits with this report.

     3.1  Amended  and  Restated  Articles  of  Incorporation  (incorporated  by
          reference to Exhibit 3.1 to Immucor,  Inc.'s  quarterly report on Form
          10-Q filed on January 16, 2001).

     3.2  Amended and Restated  Bylaws  (amended and restated as of February 12,
          2002)  (incorporated  by reference  to Exhibit 3.2 to Immucor,  Inc.'s
          quarterly report on Form 10-Q filed on April 11, 2002).

     4.1  Amended and Restated Shareholder Rights Agreement dated as of November
          20, 2001 between  Immucor,  Inc. and EquiServe Trust Company,  N.A. as
          Rights  Agent  (incorporated  by  reference to Exhibit 4.1 to Immucor,
          Inc.'s  quarterly  report on Form 10-Q filed on January 14, 2002).

(b) The  Company  did not file any  reports  on Form 8-K during the three months
    ended August 31, 2002.
<PAGE>

                                   SIGNATURES



     Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.



                                  IMMUCOR, INC.
                                  (Registrant)




Date: October 11, 2002   By:  /s/ Edward L. Gallup
      -----------------       --------------------
                              Edward L. Gallup, President and Chief Executive
                              Officer (on behalf of Registrant and as
                              Principal Executive Officer)





                               /s/ Steven C. Ramsey
                               --------------------
                               Steven C. Ramsey, Senior Vice President - Finance
                               (Principal Accounting Officer)



<PAGE>



                                 CERTIFICATIONS


I, Edward L. Gallup, certify that:


1.   I have reviewed this quarterly report on Form 10-Q of Immucor, Inc.;


2.   Based on my knowledge,  this  quarterly  report does not contain any untrue
     statement of a material fact or omit to state a material fact  necessary to
     make the statements  made, in light of the  circumstances  under which such
     statements  were made, not misleading with respect to the period covered by
     this quarterly report;


3.   Based on my  knowledge,  the  financial  statements,  and  other  financial
     information  included  in this  quarterly  report,  fairly  present  in all
     material respects the financial  condition,  results of operations and cash
     flows of the  registrant  as of, and for,  the  periods  presented  in this
     quarterly report;


4.   The  registrant's  other  certifying  officers  and I are  responsible  for
     establishing and maintaining disclosure controls and procedures (as defined
     in Exchange Act Rules 13a-14 and 15d-14) for the registrant and we have:


     a)   designed  such  disclosure  controls  and  procedures  to ensure  that
          material  information  relating  to  the  registrant,   including  its
          consolidated subsidiaries,  is made known to us by others within those
          entities,  particularly  during  the  period in which  this  quarterly
          report is being prepared;


     b)   evaluated the  effectiveness of the registrant's  disclosure  controls
          and procedures as of a date within 90 days prior to the filing date of
          this quarterly report (the "Evaluation Date"); and


     c)   presented  in  this  quarterly   report  our  conclusions   about  the
          effectiveness  of the disclosure  controls and procedures based on our
          evaluation as of the Evaluation Date;


5.   The registrant's other certifying  officers and I have disclosed,  based on
     our most recent  evaluation,  to the  registrant's  auditors  and the audit
     committee of  registrant's  board of directors (or persons  performing  the
     equivalent function):


     a)   all  significant  deficiencies  in the design or operation of internal
          controls  which could  adversely  affect the  registrant's  ability to
          record,  process,   summarize  and  report  financial  data  and  have
          identified for the  registrant's  auditors any material  weaknesses in
          internal controls; and


     b)   any fraud, whether or not material,  that involves management or other
          employees who have a  significant  role in the  registrant's  internal
          controls; and


6.   The  registrant's  other  certifying  officers and I have indicated in this
     quarterly report whether or not there were significant  changes in internal
     controls  or in other  factors  that could  significantly  affect  internal
     controls  subsequent to the date of our most recent  evaluation,  including
     any corrective actions with regard to significant deficiencies and material
     weaknesses.


Date: October 11, 2002




/s/ Edward L. Gallup
--------------------
Edward L. Gallup,
President (Chief Executive Officer)



<PAGE>



I, Steven C. Ramsey, certify that:


1.   I have reviewed this quarterly report on Form 10-Q of Immucor, Inc.;


2.   Based on my knowledge,  this  quarterly  report does not contain any untrue
     statement of a material fact or omit to state a material fact  necessary to
     make the statements  made, in light of the  circumstances  under which such
     statements  were made, not misleading with respect to the period covered by
     this quarterly report;


3.   Based on my  knowledge,  the  financial  statements,  and  other  financial
     information  included  in this  quarterly  report,  fairly  present  in all
     material respects the financial  condition,  results of operations and cash
     flows of the  registrant  as of, and for,  the  periods  presented  in this
     quarterly report;


4.   The  registrant's  other  certifying  officers  and I are  responsible  for
     establishing and maintaining disclosure controls and procedures (as defined
     in Exchange Act Rules 13a-14 and 15d-14) for the registrant and we have:


     a)   designed  such  disclosure  controls  and  procedures  to ensure  that
          material  information  relating  to  the  registrant,   including  its
          consolidated subsidiaries,  is made known to us by others within those
          entities,  particularly  during  the  period in which  this  quarterly
          report is being prepared;


     b)   evaluated the  effectiveness of the registrant's  disclosure  controls
          and procedures as of a date within 90 days prior to the filing date of
          this quarterly report (the "Evaluation Date"); and


     c)   presented  in  this  quarterly   report  our  conclusions   about  the
          effectiveness  of the disclosure  controls and procedures based on our
          evaluation as of the Evaluation Date;


5.   The registrant's other certifying  officers and I have disclosed,  based on
     our most recent  evaluation,  to the  registrant's  auditors  and the audit
     committee of  registrant's  board of directors (or persons  performing  the
     equivalent function):


     a)   all  significant  deficiencies  in the design or operation of internal
          controls  which could  adversely  affect the  registrant's  ability to
          record,  process,   summarize  and  report  financial  data  and  have
          identified for the  registrant's  auditors any material  weaknesses in
          internal controls; and


     b)   any fraud, whether or not material,  that involves management or other
          employees who have a  significant  role in the  registrant's  internal
          controls; and


6.   The  registrant's  other  certifying  officers and I have indicated in this
     quarterly report whether or not there were significant  changes in internal
     controls  or in other  factors  that could  significantly  affect  internal
     controls  subsequent to the date of our most recent  evaluation,  including
     any corrective actions with regard to significant deficiencies and material
     weaknesses.


Date: October 11, 2002




/s/ Steven C. Ramsey
--------------------
Steven C. Ramsey,
Senior Vice President - Finance (Chief Accounting Officer)


<PAGE>



EXHIBIT INDEX


Number                                      Description

     3.1  Amended  and  Restated  Articles  of  Incorporation  (incorporated  by
          reference to Exhibit 3.1 to Immucor,  Inc.'s  quarterly report on Form
          10-Q filed on January 16, 2001).

     3.2  Amended and Restated  Bylaws  (amended and restated as of February 12,
          2002)  (incorporated  by reference  to Exhibit 3.2 to Immucor,  Inc.'s
          quarterly report on Form 10-Q filed on April 11, 2002).

     4.1  Amended and Restated Shareholder Rights Agreement dated as of November
          20, 2001 between  Immucor,  Inc. and EquiServe Trust Company,  N.A. as
          Rights  Agent  (incorporated  by  reference to Exhibit 4.1 to Immucor,
          Inc.'s quarterly report on Form 10-Q filed on January 14, 2002).